TIMI Study Group
@TIMIStudyGroup
Followers
4K
Following
109
Media
162
Statuses
2K
Providing the latest news and research from the TIMI Study Group, an ARO affiliated with Brigham and Women’s Hospital and Harvard Medical School.
Boston, MA
Joined September 2013
TIMI is proud to celebrate our 40th anniversary! Since 1984, we've been dedicated to advancing the knowledge and care of patients suffering from cardiovascular disease and its risk factors. View the 40th anniversary edition of the TIMI book, now online.
1
11
62
RT @sameralsaid: Factor XI inhibition with abelacimab may be particularly attractive in AF patients with concomitant antiplatelet therapy.….
0
4
0
RT @CircAHA: Dealing with "third variables" in cardiovascular epidemiology - a review of the definitions of confounders, effect modifiers,….
0
2
0
Intensifying LDL-C lowering by adding evolocumab to statin therapy appears to provide substantial clinical benefit in individuals with T1DM and ASCVD: Time to act for these high-risk individuals! @YumiKangEndo @rgiugliano @ADA_DiabetesPro
1
10
31
FOURIER OLE complex revasc analysis highlighted in the @ESC_Journals Cardiovascular Pharmacotherapy ACC.25 summary .
0
0
1
BWH highlighting our recent NEJM publication of AZALEA-TIMI 71 trial demonstrating the substantially lower bleeding with the FXI inhibitor #abelacimab compared with rivaroxaban in AF patients.
0
2
3
Essence – TIMI 73b met its primary endpoint with olezarsen, an ASO targeting APOC3, robustly reducing levels of triglycerides! Look forward to sharing more details at an upcoming scientific congress. @BrianBergmark.
We’re pleased to announce positive topline results from our Essence study evaluating olezarsen in people with moderately elevated triglycerides. Read more: $IONS
0
2
12
Beyond the❤️: GLP-1 RAs also reduce non-CV mortality. Meta-analysis of 11 CVOTs (n=90,867) shows ↓ in all-cause, CV, and non-CV deaths in people with T2DM/obesity. @YumiKangEndo .
0
4
11
Coverage in @JWatch of @AndreZimerman's analysis of #evolocumab in patients in FOURIER TIMI 59 with autoimmune or inflammatory disease. @rgiugliano .
0
4
14
RT @AndreZimerman: Does the CV benefit of evolocumab differ in patients with autoimmune or inflammatory diseases?. The answer lies at the i….
0
13
0
RT @CircAHA: Intensive LDL-C lowering with Evolocumab may lead to greater relative reduction in cardiovascular events in patients with auto….
0
44
0
A round-up of press coverage of AZALEA-TIMI 71 primary results @rgiugliano @SidPatelMD #abelacimab .
1
5
11
RT @CardioAdvisor: From #ACC25: In patients with #AFib, #abelacimab, compared with #rivaroxaban, is associated with decreased bleeding acro….
0
2
0
RT @cardiomet_CE: 2) We are thrilled to welcome back expert author Sid Patel MD @SidPatelMD #Cardiologist @HarvardMed @TIMIStudyGroup. Sid….
0
2
0
RT @cardiomet_CE: 17) Also at #ACC25, @sameralsaid of @TIMIStudyGroup presented an analysis of the #AZALEA study by age. Now recall pts enr….
0
2
0